Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B-Reference-Cited by-同舟云学术

Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B

Published:2022-01-21 Issue:3 Volume:8 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Liu Jun¹^ORCID,Budylowski Patrick¹²,Samson Reuben³⁴,Griffin Bryan D.⁵,Babuadze Giorgi⁵,Rathod Bhavisha⁴^ORCID,Colwill Karen⁴^ORCID,Abioye Jumai A.⁶,Schwartz Jordan A.⁶^ORCID,Law Ryan⁷,Yip Lily⁵^ORCID,Ahn Sang Kyun³,Chau Serena⁷,Naghibosadat Maedeh⁵,Arita Yuko⁶^ORCID,Hu Queenie⁴,Yue Feng Yun¹^ORCID,Banerjee Arinjay⁸⁹¹⁰^ORCID,Hardy W. Rod⁴^ORCID,Mossman Karen¹¹^ORCID,Mubareka Samira⁵¹²^ORCID,Kozak Robert A.⁵,Pollanen Michael S.¹²^ORCID,Martin Orozco Natalia⁶,Gingras Anne-Claude³⁴^ORCID,Marcusson Eric G.⁶¹³^ORCID,Ostrowski Mario A.¹⁷¹⁴^ORCID

Affiliation:

1. Department of Medicine, University of Toronto, Toronto, ON, Canada.

2. Institute of Medical Science, University of Toronto, Toronto, ON, Canada.

3. Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.

4. Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada.

5. Sunnybrook Research Institute, Toronto, ON, Canada.

6. Providence Therapeutics Holdings Inc., Calgary, AB, Canada.

7. Department of Immunology, University of Toronto, Toronto, ON, Canada.

8. Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, SK, Canada.

9. Department of Veterinary Microbiology, University of Saskatchewan, Saskatoon, SK, Canada.

10. Department of Biology, University of Waterloo, Waterloo, ON, Canada.

11. Department of Medicine, McMaster University, Hamilton, ON, Canada.

12. Department of Laboratory Medicine and Pathology, University of Toronto, Toronto, ON, Canada.

13. Marcusson Consulting, San Francisco, CA, USA.

14. Keenan Research Centre for Biomedical Science of St. Michael’s Hospital, Unity Health Toronto, Toronto, ON, Canada.

Abstract

Safe and effective vaccines are needed to end the COVID-19 pandemic. Here, we report the preclinical development of a lipid nanoparticle–formulated SARS-CoV-2 mRNA vaccine, PTX-COVID19-B. PTX-COVID19-B was chosen among three candidates after the initial mouse vaccination results showed that it elicited the strongest neutralizing antibody response against SARS-CoV-2. Further tests in mice and hamsters indicated that PTX-COVID19-B induced robust humoral and cellular immune responses and completely protected the vaccinated animals from SARS-CoV-2 infection in the lung. Studies in hamsters also showed that PTX-COVID19-B protected the upper respiratory tract from SARS-CoV-2 infection. Mouse immune sera elicited by PTX-COVID19-B vaccination were able to neutralize SARS-CoV-2 variants of concern, including the Alpha, Beta, Gamma, and Delta lineages. No adverse effects were induced by PTX-COVID19-B in either mice or hamsters. Based on these results, PTX-COVID19-B was authorized by Health Canada to enter clinical trials in December 2020 with a phase 2 clinical trial ongoing.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference80 articles.

1. An interactive web-based dashboard to track COVID-19 in real time

2. Remdesivir for the Treatment of Covid-19 — Final Report

3. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

4. London School of Hygiene & Tropical Medicine;https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/.

5. World Health Organization COVID-19 vaccine tracker and landscape;https://who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaccine targeting to mucosal lymphoid tissues promotes humoral immunity in the gastrointestinal tract;Science Advances;2024-05-31

2. Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity;Molecular Therapy;2024-05

3. A potential bivalent mRNA vaccine candidate protects against both RSV and SARS-CoV-2 infections;Molecular Therapy;2024-04

4. Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study;Scientific Reports;2024-03-04

5. Host Genetic Variation Impacts SARS-CoV-2 Vaccination Response in the Diversity Outbred Mouse Population;Vaccines;2024-01-20